The present invention relates to a novel tetraazacyclododecan-tetraone derivative or pharmaceutically acceptable salts thereof, and to a pharmaceutical composition containing same for preventing or treating cancer. The novel tetraazacyclododecan-tetraone derivative according to the present invention suppresses the growth of tumor cells through RUNX3 expression and activation, has the effect of inducing cell death as well as of inhibiting cell movement and cell invasion, and has the effect of reducing the size of tumors, and is thus capable of being effectively used as an anticancer agent.La présente invention concerne un nouveau dérivé tétraazacyclododécane-tétraone ou des sels pharmaceutiquement acceptables de celui-ci, et une composition pharmaceutique contenant celui-ci pour la prévention ou le traitement du cancer. Le nouveau dérivé tétraazacyclododécane-tétraone selon la présente invention inhibe la croissance des cellules tumorales par lintermédiaire de lexpression et de lactivation de RUNX3, a leffet dinduire la mort cellulaire ainsi que dinhiber le mouvement cellulaire et linvasion cellulaire, et a leffet de réduire la dimension des tumeurs, et est, par conséquent, capable dêtre utilisé efficacement en tant quagent anticancéreux.본 발명은 신규한 테트라아자사이클로도데칸-테트라온 유도체 또는 이의 약학적으로 허용 가능한 염, 및 이를 함유하는 암 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 신규한 테트라아자사이클로도데칸-테트라온 유도체는 렁스3 발현 및 활성 유도를 통해 종양세포의 성장을 억제하고, 세포사멸을 유도할 뿐만 아니라, 세포 이동저해 효과와 세포 침습을 저해하는 효과가 있고, 종양의 크기를 감소시키는 효과가 있으므로 항암제로 유용하게 이용될 수 있다.
